Active substance
Calcitriol
- SFDA 5
- US FDA 24
- Health Canada 6
- US price lines 3
- NHS prices 3
- WHO EML 1
- Safety 1
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| Rocaltrol | 0.25 µg | Capsule, soft · Oral use | 100 Blister | SAR 136.20 | NCE · Prescription | Atnahs Pharma UK Limited | Valid |
| CALCIJEX 1MCG-ML I.V. AMP | 1 µ/ml | Solution · Intravenous use | 1 Ampoule | SAR 22.50 | NCE · Prescription | Abbott Laboratories | Withdrawn by MAH · Not Marketed |
| CALCIJEX 2MCG-ML AMP | 2 µ/ml | Solution · Intravenous use | 1 Ampoule | SAR 36.25 | NCE · Prescription | Abbott Laboratories | Withdrawn by MAH · Not Marketed |
| ROCALTROL CAP 0.25MCG | 0.25 µg | Capsule · Oral use | 30 Blister | SAR 53.75 | NCE · Prescription | ROCHE | Withdrawn by MAH · Not Marketed |
| ROCALTROL CAP 0.5MCG | 0.5 µg | Capsule · Oral use | 30 Blister | SAR 94.80 | NCE · Prescription | ROCHE | Withdrawn by MAH · Not Marketed |
Indications — CHI Daman Drug Formulary
HYPERPARATHYRODISM
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| ROCALTROL | 0.25MCG; 0.5MCG | capsule · oral | ESJAY PHARMA | Prescription | 17 Aug 1978 |
| ROCALTROL | 1MCG/ML | solution · oral | ESJAY PHARMA | Prescription | 20 Nov 1998 |
| CALCITRIOL | 0.25MCG; 0.5MCG | capsule · oral | TEVA | Prescription | 12 Oct 2001 |
| CALCITRIOL | 1MCG/ML | solution · oral | HIKMA PHARMS | Prescription | 18 Jul 2003 |
| CALCITRIOL | 0.25MCG | capsule · oral | HIKMA PHARMS | Prescription | 27 Mar 2006 |
| CALCITRIOL | 0.001MG/ML | injectable · injection | LONG GROVE PHARMS | Prescription | 29 Jan 2008 |
| VECTICAL | 3MCG/GM | ointment · topical | GALDERMA LABS LP | Prescription | 23 Jan 2009 |
| CALCITRIOL | 0.25MCG; 0.5MCG | capsule · oral | BIONPHARMA | Prescription | 24 May 2013 |
| CALCITRIOL | 0.25MCG; 0.5MCG | capsule · oral | ONESOURCE SPECIALTY | Prescription | 12 Dec 2014 |
| CALCITRIOL | 0.5MCG; 0.25MCG | capsule · oral | AMNEAL PHARMS | Prescription | 14 Jun 2017 |
| CALCITRIOL | 1MCG/ML | solution · oral | RISING | Prescription | 21 Nov 2018 |
| CALCITRIOL | 0.001MG/ML | injectable · injection | GLAND | Prescription | 3 Feb 2020 |
| CALCITRIOL | 1MCG/ML | solution · oral | ANDA REPOSITORY | Prescription | 28 Jul 2023 |
| CALCITRIOL | 0.25MCG; 0.5MCG | capsule · oral | HUMANWELL PURACAP | Prescription | 27 Feb 2026 |
| CALCIJEX | 0.001MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; 0.002MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | injectable · injection | ABBVIE | Discontinued | 25 Sep 1986 |
| CALCITRIOL | 0.001MG/ML; 0.002MG/ML | injectable · injection | FRESENIUS KABI USA | Discontinued | 31 Dec 2002 |
| CALCITRIOL | 0.001MG/ML; 0.002MG/ML | injectable · injection | FRESENIUS MEDCL | Discontinued | 20 Feb 2003 |
| CALCITRIOL | 0.001MG/ML; 0.002MG/ML | injectable · injection | TEVA PARENTERAL | Discontinued | 31 Mar 2003 |
| CALCITRIOL | 0.001MG/ML | injectable · injection | ROCKWELL MEDCL | Discontinued | 17 Sep 2003 |
| CALCITRIOL | 0.001MG/ML; 0.002MG/ML | injectable · injection | AM REGENT | Discontinued | 26 Sep 2003 |
| CALCITRIOL | 0.001MG/ML; 0.002MG/ML | injectable · injection | HOSPIRA | Discontinued | 16 Jan 2004 |
| CALCITRIOL | 0.001MG/ML | injectable · injection | SAGENT PHARMS | Discontinued | 8 Feb 2006 |
| CALCITRIOL | 0.002MG/ML | injectable · injection | LONG GROVE PHARMS | Discontinued | 29 Jan 2008 |
| CALCITRIOL | 0.25MCG; 0.5MCG | capsule · oral | SUN PHARM | Discontinued | 21 Feb 2019 |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| CALCITRIOL-ODAN | 02431637 | 0.25 MCG | CAPSULE · ORAL | ODAN LABORATORIESLTD |
| CALCITRIOL-ODAN | 02431645 | 0.5 MCG | CAPSULE · ORAL | ODAN LABORATORIESLTD |
| ROCALTROL | 00481815 | 0.5 MCG | CAPSULE · ORAL | SEARCHLIGHT PHARMA INC |
| ROCALTROL | 00481823 | 0.25 MCG | CAPSULE · ORAL | SEARCHLIGHT PHARMA INC |
| TARO-CALCITRIOL | 02485710 | 0.25 MCG | CAPSULE · ORAL | TARO PHARMACEUTICALS INC |
| TARO-CALCITRIOL | 02485729 | 0.5 MCG | CAPSULE · ORAL | TARO PHARMACEUTICALS INC |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | CALCITRIOL 0.25 MCG CAPSULE | $0.15317 | per EA | 7 Oct 2026 |
| US NADAC | CALCITRIOL 0.5 MCG CAPSULE | $0.23399 | per EA | 7 Oct 2026 |
| US NADAC | CALCITRIOL 1 MCG/ML SOLUTION | $6.60188 | per ML | 23 Sep 2026 |
| NHS Drug Tariff | Calcitriol 250nanogram capsules | £18.04 | 100 capsule | 1 Oct 2026 |
| NHS Drug Tariff | Calcitriol 3micrograms/g ointment | £18.06 | 100 gram | 1 Oct 2026 |
| NHS Drug Tariff | Calcitriol 500nanogram capsules | £32.25 | 100 capsule | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 13.4. Dermatological medicines > Medicines affecting skin differentiation and proliferation · core
Therapeutic equivalent to calcipotriol for Psoriasis of unspecified type
Safety signals and safety-related labeling changes
- US FDA 17 Jul 2020 VECTICAL — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.